Clinical trial
A Multi-Center, Phase 2, Open Label Study of Safety and Efficacy of Oral Recombinant Human Lactoferrin (rhLF) Monotherapy in Patients With Advanced Renal Cell Carcinoma (RCC), Who Have Failed at Least One Regimen of Systemic Therapy for RCC
NCT00095186 is registered in ClinicalTrials.gov with Agennix as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Phase 2, Open Label Study of Safety and Efficacy of Oral Recombinant Human Lactoferrin (rhLF) Monotherapy in Patients With Advanced Renal Cell Carcinoma (RCC), Who Have Failed at Least One Regimen of Systemic Therapy for RCC
- Lead sponsor
- Agennix
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2004
- Completion date
- March 31, 2007
- Enrollment
- 40
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.